Orthofix Medical Future Growth

Future criteria checks 0/6

Orthofix Medical is forecast to grow earnings and revenue by 76.4% and 6.5% per annum respectively while EPS is expected to grow by 79.9% per annum.

Key information

76.4%

Earnings growth rate

79.9%

EPS growth rate

Medical Equipment earnings growth	16.2%
Revenue growth rate	6.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	22 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqGS:OFIX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	908	-6	N/A	N/A	3
12/31/2025	847	-33	N/A	111	4
12/31/2024	791	-56	N/A	92	4
12/31/2023	747	-151	-108	-46	N/A
9/30/2023	668	-136	-91	-37	N/A
6/30/2023	598	-118	-76	-38	N/A
3/31/2023	529	-76	-69	-38	N/A
12/31/2022	461	-20	-35	-12	N/A
9/30/2022	464	-45	-27	-2	N/A
6/30/2022	462	-37	-17	6	N/A
3/31/2022	465	-37	-13	8	N/A
12/31/2021	464	-38	-1	18	N/A
9/30/2021	457	-15	12	29	N/A
6/30/2021	456	-8	21	44	N/A
3/31/2021	407	-29	41	64	N/A
12/31/2020	407	3	50	74	N/A
9/30/2020	410	24	42	64	N/A
6/30/2020	413	-22	37	54	N/A
3/31/2020	456	-4	28	46	N/A
12/31/2019	460	-28	9	32	N/A
9/30/2019	460	-31	15	41	N/A
6/30/2019	458	8	20	45	N/A
3/31/2019	453	9	29	52	N/A
12/31/2018	453	14	33	50	N/A
9/30/2018	449	6	43	59	N/A
6/30/2018	442	11	40	57	N/A
3/31/2018	440	15	29	46	N/A
12/31/2017	434	7	22	39	N/A
9/30/2017	425	1	N/A	15	N/A
6/30/2017	419	8	N/A	19	N/A
3/31/2017	414	-3	N/A	29	N/A
12/31/2016	410	3	N/A	59	N/A
9/30/2016	406	11	N/A	55	N/A
6/30/2016	409	0	N/A	56	N/A
3/31/2016	405	10	N/A	46	N/A
12/31/2015	396	-2	N/A	44	N/A
9/30/2015	392	-10	N/A	42	N/A
6/30/2015	392	-9	N/A	42	N/A
3/31/2015	392	-10	N/A	64	N/A
12/31/2014	402	-4	N/A	51	N/A
9/30/2014	408	-8	N/A	51	N/A
6/30/2014	399	-25	N/A	51	N/A
3/31/2014	395	-26	N/A	42	N/A
12/31/2013	398	-18	N/A	67	N/A
9/30/2013	402	8	N/A	-6	N/A
6/30/2013	418	35	N/A	-13	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OFIX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OFIX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OFIX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OFIX's revenue (6.5% per year) is forecast to grow slower than the US market (8.2% per year).

High Growth Revenue: OFIX's revenue (6.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if OFIX's Return on Equity is forecast to be high in 3 years time

Orthofix Medical Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 12%

Orthofix Medical Inc. Provides Earnings Guidance for the Year 2024

Consensus EPS estimates upgraded to US$3.50 loss, revenue downgraded

Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Price target decreased by 11% to US$29.00

Consensus EPS estimates fall by 12%

Recent updates

Orthofix Medical Inc., Annual General Meeting, Jun 18, 2024

Orthofix Medical Inc. to Report Q1, 2024 Results on May 07, 2024

New minor risk - Profitability

Orthofix Medical Inc. Appoints Andres Cedron as New Chief Legal Officer

Orthofix Medical Inc. Announces Board Resignation

Orthofix Medical Inc. Appoints Lucas Vitale as Chief People and Business Operations Officer

Consensus EPS estimates fall by 12%

Full year 2023 earnings: EPS misses analyst expectations

Orthofix Medical Inc. Provides Earnings Guidance for the Year 2024

Orthofix Medical Inc. to Report Q4, 2023 Results on Mar 05, 2024

Orthofix Medical Inc. Names Massimo Calafiore as President and Member of the Board of Directors Effective Immediately

Orthofix Medical Inc. Appoints Julie Andrews as Chief Financial Officer

Orthofix Announces Publication of New Data Supporting Use of PEMF Stimulation in Lumbar Spine Fusion Procedures for Patients at Risk of Pseudarthrosis

Orthofix Medical Inc. Announces Board Changes

Orthofix Medical Inc. Appoints Massimo Calafiore as Chief Executive Officer, Effective in Early 2024

Consensus EPS estimates upgraded to US$3.50 loss, revenue downgraded

Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Orthofix Medical Inc. Announces Full Commercial Launch of the Waveform L Interbody System for Lateral Lumbar Fusion Procedures

Orthofix Medical Inc. to Report Q3, 2023 Results on Nov 08, 2023

Orthofix Medical Inc. Announces 510k Clearance and Full Commercial Launch of OsteoCove, an Advanced Bioactive Synthetic Graft for Use in Spine and Orthopedic Procedures

Orthofix Medical Inc. Announces First Patient Procedures and Full Commercial Launch of the Galaxy Fixation Gemini System and Expanded Sterile Kit Offerings for Orthopedic Trauma Procedures

Independent Director recently bought US$101k worth of stock

Orthofix Medical Inc. Announces Management Appointments

Orthofix Medical Inc. Announces Management Changes

Price target decreased by 11% to US$29.00

Consensus EPS estimates fall by 12%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Orthofix Medical Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target decreased by 12% to US$32.67

Orthofix Medical Inc. Introduces New Phantom and Tornado Hins for Truelok Ring Fixation Systems

Orthofix Medical Inc. Announces Changes to Board of Directors

Orthofix Medical Inc Announces the Full Commercial Launch of WaveForm A 3D Printed Anterior Lumbar Interbody

Orthofix Medical Inc. Announces First Presentation of Seven-Year Outcome Data for the M6-C Artificial Cervical Disc with Other Clinical and Scientific Abstracts At the Isass Annual Meeting

President of Global Spine Business recently sold US$157k worth of stock

President of Global Spine Business notifies of intention to sell stock

Consensus EPS estimates fall by 81%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Orthofix Medical Inc. Revises Sales Guidance for the Year 2023

Consensus revenue estimates decrease by 18%

Full year 2022 earnings: EPS misses analyst expectations

High number of new directors

Orthofix Announces Full Commercial Launch and First Patient Cases of Mariner Deformity System

Orthofix Medical Inc. Provides Unaudited Preliminary Net Sales Results Fourth Quarter and Full Year Ended December 31, 2022

Orthofix Medical Inc. Announces CEO Changes

Orthofix Medical Inc. Announces Publication of Data Demonstrating the Clinical Benefits of Trinity Elite Cellular Bone Allograft in Lumbar Fusion Procedures

Two unknown private equity fund sponsors submitted a non-binding indication of interest to acquire Orthofix Medical Inc. (NasdaqGS:OFIX) for approximately $460 million.

Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

Price target decreased to US$33.67

High number of new directors

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Orthofix Medical Inc. Provides Financial Guidance for the Full Year 2022

Orthofix Medical (NASDAQ:OFIX) Is In A Good Position To Deliver On Growth Plans

Orthofix Medical Inc. to Report Q3, 2022 Results on Nov 03, 2022

Orthofix Announces First Patient Implants with Legacy Demineralized Bone Matrix for Spine, Pelvic and Extremities Procedures

Orthofix Medical Inc. (NasdaqGS:OFIX) entered into a definitive agreement to acquire SeaSpine Holdings Corporation (NasdaqGS:SPNE) for approximately $280 million in a merger of equals transaction.

Consensus forecasts updated

Orthofix Medical Inc. (NasdaqGS:OFIX) entered into a definitive agreement to acquire SeaSpine Holdings Corporation (NasdaqGS:SPNE) for approximately $280 million in a merger of equals transaction.

Orthofix stock falls amid SeaSpine merger despite rise in prelim Q3 revenue

Orthofix Medical Inc. Revises Financial Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations

Orthofix inks licensing deal with CGBio for bone graft product Novosis

Orthofix Medical Inc. to Report Q2, 2022 Results on Aug 05, 2022

Orthofix Announces First Clinical Use of Virtuos Lyograft – A First-Of-Its-Kind, Shelf-Stable and Complete Autograft Substitute for Spine and Orthopedic Procedures

Consensus forecasts updated

Price target decreased to US$46.83

Estimating The Fair Value Of Orthofix Medical Inc. (NASDAQ:OFIX)